Sonnet BioTherapeutics Advances Pancreatic Cancer Drug Trial
PremiumCompany AnnouncementsSonnet BioTherapeutics Advances Pancreatic Cancer Drug Trial
30d ago
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
Premium
Press Releases
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
1M ago
Sonnet enters into collaboration agreement with Sarcoma Oncology Center
Premium
The Fly
Sonnet enters into collaboration agreement with Sarcoma Oncology Center
1M ago
Sonnet BioTherapeutics reports data from Phase 1b/2a trial of SON-080
PremiumThe FlySonnet BioTherapeutics reports data from Phase 1b/2a trial of SON-080
2M ago
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
Premium
Press Releases
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
2M ago
Sonnet BioTherapeutics files to sell 5.77M shares of common stock for holders
Premium
The Fly
Sonnet BioTherapeutics files to sell 5.77M shares of common stock for holders
2M ago
Sonnet BioTherapeutics announces review of strategic alternatives
PremiumThe FlySonnet BioTherapeutics announces review of strategic alternatives
4M ago
Sonnet BioTherapeutics announces updated clinical data for SON-1010
Premium
The Fly
Sonnet BioTherapeutics announces updated clinical data for SON-1010
4M ago
Sonnet BioTherapeutics price target lowered to $7 from $11 at EF Hutton
Premium
The Fly
Sonnet BioTherapeutics price target lowered to $7 from $11 at EF Hutton
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100